Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality business Quality Strong, Valuation Fairly Valued, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #100 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 13 Jun 2025 | TRADE CORNER | Bulk | Sell | 235,200 | 120.2900 | NSE |
| 31 Jan 2025 | NECTA BLOOM VCC - NECTA BLOOM ONE | Bulk | Buy | 275,000 | 102.7500 | NSE |
| 31 Jan 2025 | MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITED | Bulk | Sell | 275,000 | 102.7500 | NSE |
| 24 Jan 2025 | MONEY LOGIX SECURITIES PVT LTD | Bulk | Buy | 550,000 | 105.7800 | NSE |
| 24 Jan 2025 | JAINAM BROKING LIMITED | Bulk | Sell | 550,000 | 105.7700 | NSE |
| 6 Oct 2023 | PRABHULAL LALLUBHAI PAREKH | Bulk | Buy | 529,365 | 168.3200 | NSE |
| 6 Oct 2023 | NIRAJ RAJNIKANT SHAH | Bulk | Buy | 650,000 | 162.1500 | NSE |
| 6 Oct 2023 | ALPHA ALTERNATIVES MSAR LLP | Bulk | Sell | 299,127 | 162.8400 | NSE |
| 6 Oct 2023 | ALPHA ALTERNATIVES FINANCIAL SERVICES PRIVATE LIMITED | Bulk | Sell | 224,127 | 163.0100 | NSE |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 18 Jul 2025 | RIGHTS | Rights 1:4 @ Premium Rs 65/- |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 10 Aug 2026 | Financial Results | Yes |
| 14 May 2026 | Financial Results | Yes |
| 11 Feb 2026 | Financial Results | Yes |
| 11 Nov 2025 | Financial Results | Yes |
| 8 Aug 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
